Company Overview of Aesica Pharmaceuticals Limited
Aesica Pharmaceuticals Limited provides pharmaceutical contract development and manufacturing services. The company offers potency drug substance and drug manufacturing services that include the production of highly potent active pharmaceutical ingredients; formulation development, analytics, and GMP services for pharmaceutical dosage forms that include tablets, capsules, liquids, suspensions, creams, ointments, and inhaled pharmaceuticals; and finished dose manufacturing services, such as wet granulation, tablet production, encapsulation, liquid manufacturing, temperature critical, blister packaging, and bottle packing. It serves pharmaceutical, biotech, and life science companies, as well ...
Quorum Business Park
Newcastle upon Tyne, NE12 8BS
Founded in 2004
Key Executives for Aesica Pharmaceuticals Limited
Head of Quality - Cramlington Facility
Compensation as of Fiscal Year 2015.
Aesica Pharmaceuticals Limited Key Developments
Aesica Announces Board Appointments
Oct 20 14
Aesica announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany. Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. Sven Wrabletz reports to Detlef Behrens.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries